AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX 14,068
-424 (-2.93%)
Apr 24, 2026, 11:37 AM GMT
AstraZeneca Employees
AstraZeneca had 96,100 employees as of December 31, 2025. The number of employees increased by 1,800 or 1.91% compared to the previous year.
Employees
96,100
Change (1Y)
1,800
Growth (1Y)
1.91%
Revenue / Employee
454.14K GBP
Profits / Employee
79.05K GBP
Market Cap
224.77B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96,100 | 1,800 | 1.91% |
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GSK plc | 66,841 |
| Haleon | 24,535 |
| Smith & Nephew | 16,988 |
| Convatec Group | 10,910 |
| Hikma Pharmaceuticals | 9,400 |
| CVS Group | 9,000 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,796 |
AstraZeneca News
- 2 days ago - T Rowe Price Equity Income Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - GuruFocus
- 2 days ago - AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in IgAN Treatment - GuruFocus
- 2 days ago - Germany risks missing out on new drugs, AstraZeneca CEO tells paper - Reuters
- 3 days ago - AstraZeneca I CAN Phase III Interim Analysis Meets Primary Goal - Finanz Nachrichten
- 3 days ago - AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease - Reuters
- 3 days ago - AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab - GuruFocus
- 3 days ago - Tozorakimab (AZN) Shows Promise in COPD Treatment in Phase III Trial - GuruFocus
- 3 days ago - Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - Business Wire